UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011851
Receipt number R000013852
Scientific Title The efficacy of vildagliptin on type 2 diabetic patients with basal-bolus insulin therapy in the short-term hospitalization (single-center, randomized, open-label, controlled study).
Date of disclosure of the study information 2013/09/24
Last modified on 2013/09/24 16:38:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The efficacy of vildagliptin on type 2 diabetic patients with basal-bolus insulin therapy in the short-term hospitalization (single-center, randomized, open-label, controlled study).

Acronym

The efficacy of vildagliptin on type 2 diabetic patients with basal-bolus insulin therapy in the short-term hospitalization.

Scientific Title

The efficacy of vildagliptin on type 2 diabetic patients with basal-bolus insulin therapy in the short-term hospitalization (single-center, randomized, open-label, controlled study).

Scientific Title:Acronym

The efficacy of vildagliptin on type 2 diabetic patients with basal-bolus insulin therapy in the short-term hospitalization.

Region

Japan


Condition

Condition

Type 2 Diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Clarify the efficacy of the administration of vildagliptin on the control of plasma glucose and serum lipid

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

The daily profile of plasma glucose and serum lipid at discherge.

Key secondary outcomes

the required dose of insulin infusion to maintain the blood glucose normal.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

insulin alone group
From admission, adjust the insulin dose to keep blood glucose of before each meal less than 120mg/dl without vildagliptin administration.

Interventions/Control_2

insulin plus vildagliptin group
From admission, adjust the insulin dose to keep blood glucose of before each meal less than 120mg/dl with vildagliptin

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

Type 2 diabetic patients who were admitted for diabetic control to Nippon Medical School Chiba-Hokusoh hospital

Key exclusion criteria

The subjects were excluded, if they were treated with insulin, DPP-4I or GLP-1 receptor agonist, have a history or evidence of liver or endocrine disease, recent myocardial infarction, cerebral vascular disease, heart failure, infectious disease, pregnancy or any carcinoma.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Fumitaka Okajima

Organization

Nippon Medical School, Chiba-Hokusoh Hospital

Division name

Division of Endocrinology, Department of Medicine

Zip code


Address

1715 Kamagari, Inzai, Chiba

TEL

0476-99-1111

Email

okaji@nms.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Fumitaka Okajima

Organization

Nippon Medical School, Chiba-Hokusoh Hospital

Division name

Division of Endocrinology, Department of Medicine

Zip code


Address

1715 Kamagari, Inzai, Chiba

TEL

0476-99-1111

Homepage URL


Email

okaji@nms.ac.jp


Sponsor or person

Institute

Nippon Medical School, Chiba-Hokusoh Hospital, Division of Endocrinology, Department of Medicine

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

日本医大千葉北総病院(千葉県)


Other administrative information

Date of disclosure of the study information

2013 Year 09 Month 24 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 07 Month 31 Day

Date of IRB


Anticipated trial start date

2012 Year 08 Month 06 Day

Last follow-up date

2013 Year 05 Month 09 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 09 Month 24 Day

Last modified on

2013 Year 09 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013852


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name